Journal articles on the topic 'Coronary heart disease Complications Prevention'
To see the other types of publications on this topic, follow the link: Coronary heart disease Complications Prevention.
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Coronary heart disease Complications Prevention.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Alpert, Joseph S. "Coronary Heart Disease: Prevention, Complications, and Treatment." JAMA: The Journal of the American Medical Association 253, no. 24 (June 28, 1985): 3609. http://dx.doi.org/10.1001/jama.1985.03350480119039.
Full text
2
Kirichenko, A. A. "Coronary heart disease and inflammation." Clinical Medicine (Russian Journal) 96, no. 8 (December 20, 2018): 688–95. http://dx.doi.org/10.18821/0023-2149-2018-96-8-688-695.
Full textAbstract:
The increased content of inflammation markers in the blood is a significant prognostic sign of coronary events in persons with stable or asymptomatic course of coronary heart disease (CHD) and suggests that the inflammation underlying the destabilization of CHD has an independent character and is largely independent of the severity of stenotic lesions of coronary vessels. Activation of the local inflammatory process in the atherosclerotic plaque leads to the destruction of the fibrous capsule in combination with an increase in the activity of cellular and plasma factors of the coagulation system and inhibition of the fibrinolytic system. Cytomegalovirus, Chlamydia pneumoniae, pathogens of periodontal disease are nominated for the role of inducers of inflammatory reactions. The synergistic effect of several pathogens is reflected in the concept of burden of infection (“infectious burden”). Immuno-inflammatory rheumatic diseases are characterized by a high risk of cardiovascular complications. An important place in their prevention is an effective anti-inflammatory therapy: methotrexate, suppressing the formation of interleukin 1ft and tumor necrosis factor a, allows not only to modify the course of the disease, but also to reduce the risk of cardiovascular accidents. Chronic inflammation, as a key element of atherosclerosis pathogenesis, can be caused not only by infectious and immune factors, but also by metabolic factors. The activation of inflammasomes induced by cholesterol crystals in macrophages is an important link between cholesterol metabolism and inflammation in atherosclerotic plaques. Confirmation of the important pathogenetic role of inflammation is to reduce the risk of cardiovascular complications (CVD) on the background of anti-inflammatory therapy. In statin therapy, the decrease in The level of C-reactive protein (CRP) was significantly correlated with the suppression of atherosclerosis progression and a decrease in the risk of SSR, regardless of the degree of lowering the low-density lipoprotein cholesterol level. Taking colchicine in a low dose in patients with stable coronary artery disease, who received standard therapy, reduced the risk of acute coronary syndrome and sudden cardiac death. Secondary prevention of cardiovascular complications by human monoclonal antibodies to interleukin 1ft (kanakinumab) led to a decrease in the risk of SSR regardless of sex, Smoking, and lipid levels.
3
Ivanova, Anastasia S., and Maxim L. Kasyanik. "Effect of Catecholamines on Haemostasis Indicators in Coronary Heart Disease." Bulletin of Rehabilitation Medicine 21, no. 3 (June 30, 2022): 129–36. http://dx.doi.org/10.38025/2078-1962-2022-21-3-129-136.
Full textAbstract:
The concentration of catecholamines, having positive inotropic and chronotropic effects on heart function, increases under the action of strong stimuli. This mechanism of influence is very important in terms of the development of both coronary and non-coronary myocardial damage. However, further studies have revealed an important role of catecholamines in the regulation of hemostasis processes, which is very relevant in patients with coronary heart disease, as it increases the risk of myocardial infarction. Aim. Based on the literature data, to study the role of catecholamines in the regulation of the hemostasis system as a risk factor for complications in coronary heart disease. Material and methods. We analyzed literature sources in the computer databases «Cyberlennica», «PubMed», «eLibrary» using the search words: «сatecholamines – hemostasis», «сatecholamines – platelets», «сatecholamines – leukocytes», «coronary heart disease – сatecholamines», «coronary heart disease – hemostasis», «coronary heart disease – platelets». The analyzed literature describes the results of original studies that characterize the multifactorial influence of catecholamines on the hemostasis system in the coronary heart disease: the effects of these hormones as an important activator of the platelet hemostasis, the role of platelets in activating the coagulation component of hemostasis and its specific features, the importance of leukocytes, erythrocytes, endothelium, changes in the lipid profile in disorders of the blood coagulation process. Therefore, regular monitoring of its condition, timely pharmacological correction is necessary to ensure effective relapse prevention and reduce the risk of complications and fatal outcome. Conclusion. Regular monitoring of the hemostasis system and timely pharmacological correction are necessary to ensure effective relapse prevention and reduce the risk of complications and fatal outcome in patients with coronary heart disease.
4
Vogralik, V. G., M. T. Saltseva, N. V. Amineva, and V. I. Klemenov. "Value of antithrombotic therapy in patients with coronary heart disease." Kazan medical journal 69, no. 5 (October 15, 1988): 341–43. http://dx.doi.org/10.17816/kazmj98431.
Full textAbstract:
Numerous studies have shown that intravascular thrombosis is one of the main causes of death in patients with coronary heart disease. Therefore, the issues of prevention of thromboembolic complications and development of the tactics of differentiated antithrombotic therapy in coronary heart disease, including chronic forms of the disease, are extremely relevant.
5
Aquarista, Nindara Citra. "Differences Characteristics Patients Diabetes Mellitus Type 2 with and without Coronary Heart Disease." Jurnal Berkala Epidemiologi 5, no. 1 (April 28, 2017): 37. http://dx.doi.org/10.20473/jbe.v5i1.2017.37-47.
Full textAbstract:
Diabetes mellitus is the third highest Non-Communicable Diseases (NCDs), which causes death in Indonesia. The incidence of coronary heart disease in diabetes mellitus is high, 65% of people with diabetes mellitus die due to coronary heart disease and stroke. The purpose of this study is to analyze the differences in the characteristics of Diabetes mellitus type 2 in patients with and without coronary heart disease in Haji General Hospital Surabaya year 2016. This research uses observational analysis with cross sectional study design.The subject of the study is the incidence of diabetes Mellitus type 2 with and without coronary heart disease with undergoing outpatient treatment at Haji General Hospital Surabaya year 2016. The Samples were taken by fixed-disease sampling method with 42 people as the samples. The data analysis uses Chi Square test. The results show for the independent variables that have the most significant difference inHaji General Hospital Surabaya year 2016 is smoking behavior (p = 0.00; PR = 7.85; 95% CI = 2.09 to 29.50) and hypertension (p= 0,002; PR = 3.51; 95% CI = 1.42 to 8.67). In conclusion, the smoking behavior and hypertension can lead to complications of coronary heart disease for patients with type in Diabetes Mellitus type 2 in Haji General Hospital year 2016. It needs awareness to check blood pressure regularly and eliminate the smoking habit as the prevention of complications of coronary heart disease for patients with diabetes mellitus type 2.Keywords: diabetes mellitus type 2, coronary hearth disease.
6
Aquarista, Nindara Citra. "Differences Characteristics Patients Diabetes Mellitus Type 2 with and without Coronary Heart Disease." Jurnal Berkala Epidemiologi 5, no. 1 (April 28, 2017): 37. http://dx.doi.org/10.20473/jbe.v5i12017.37-47.
Full textAbstract:
Diabetes mellitus is the third highest Non-Communicable Diseases (NCDs), which causes death in Indonesia.The incidence of coronary heart disease in diabetes mellitus is high, 65% of people with diabetes mellitus die due to coronary heart disease and stroke. The purpose of this study is to analyze the differences in the characteristics of Diabetes mellitus type 2 in patients with and without coronary heart disease in Haji General Hospital Surabaya year 2016. This research uses observational analysis with cross sectional study design. The subject of the study is the incidence of diabetes Mellitus type 2 with and without coronary heart disease with undergoing outpatient treatment at Haji General Hospital Surabaya year 2016. The Samples were taken by fixed-disease sampling method with 42 people as the samples. The data analysis uses Chi Square test. The results show for the independent variables that have the most significant difference inHaji General Hospital Surabaya year 2016 is smoking behavior (p = 0.00; PR = 7.85; 95% CI = 2.09 to 29.50) and hypertension (p = 0,002; PR = 3.51; 95% CI = 1.42 to 8.67). In conclusion, the smoking behavior and hypertension can lead to complications of coronary heart disease for patients with type in Diabetes Mellitus type 2 in Haji General Hospital year 2016. It needs awareness to check blood pressure regularly and eliminate the smoking habit as the prevention of complications of coronary heart disease for patients with diabetes mellitus type 2.Keywords: diabetes mellitus type 2, coronary hearth disease.
7
Taratukhin, E. O. "Arterial hypertension and coronary heart disease: the place of angiotensin II receptor antagonists." Cardiovascular Therapy and Prevention 11, no. 6 (December 20, 2012): 78–80. http://dx.doi.org/10.15829/1728-8800-2012-6-78-80.
Full textAbstract:
The paper considers arterial hypertension and coronary heart disease as pathologies which share multiple pathogenetic mechanisms. The role of angiotensin II receptor antagonists (ARA) in the effective treatment of these diseases and in prevention of their complications is discussed. The modern views on ARA and their indications are presented.
8
Budi Yuli Setianto and Andika Putra. "Radiation-Induced Heart Disease: From Diagnosis to Prevention." ACI (Acta Cardiologia Indonesiana) 7, no. 1 (March 23, 2021): 31–35. http://dx.doi.org/10.22146/jaci.v7i1.544.
Full textAbstract:
Radiotherapy has become an important component of multimodal treatment of malignancy. After 50 years, there was a drastic increase in outcomes of patients with malignancy. However, improvement of the survival is also accompanied by some inevitable complications on cardiovascular system which are often called radiation-induced heart disease (RIHD). RIHD comprises a spectrum of heart disease including pericardial disease, coronary artery disease, valvular heart disease, conduction system abnormalities, cardiomyopathy, and medium or large vessel vasculopathy. The underlying mechanisms include direct effects on function and structure of the heart, or accelerate development of cardiovascular disease, especially with the presence of previous cardiovascular risk factors. Recent studies have identified non-invasive methods for evaluation of RIHD. Furthermore, potential options preventing or at least attenuating RIHD have been developed. This review provides an overview of pathogenesis, clinical manifestation, diagnosis, management, and prevention of RIDH.
Keywords: malignancy, radiotherapy, radiation - induced heart disease.
9
Dąbrowski, Rafał. "Cardiological complications in the course of influenza and COVID-19." In a good rythm 1, no. 54 (April 30, 2020): 4–9. http://dx.doi.org/10.5604/01.3001.0014.1501.
Full textAbstract:
Cardiac complications associated with the acute or chronic form of influenza and COVID-19 infection occur in < 10% of cases. They may affect pericardium, myocardium or coronary arteries which finally results in heart failure or in case of pericarditis – fluid in the pericardium and tamponade risk. A relationship has been demonstrated between influenza epidemics and an increased incidence of acute coronary syndromes. An important complication of influenza infection may be myocarditis and subsequent heart failure. Arrhythmias, in various forms and with varying degrees of severity, can occur at any stage of the disease. The possibility of sudden deaths in the course of influenza virus infection has been reported. The treatment of a patient with cardiovascular involvement should be multidirectional: causal, symptomatic and prophylactic in the aspect of heart failure prevention. The knowledge about cardiovascular complications in the course of SARS-CoV-2 infection is increasing. Despite the possibility of using antiviral drugs in treatment, prevention by vaccination still remains the most effective therapeutic method.
10
Shafter, Ahmed M., Kashif Shaikh, Amit Johanis, and Matthew J. Budoff. "De-risking primary prevention: role of imaging." Therapeutic Advances in Cardiovascular Disease 15 (January 2021): 175394472110512. http://dx.doi.org/10.1177/17539447211051248.
Full textAbstract:
Atherosclerotic cardiovascular disease (ASCVD) is a common disease among the general population, and includes four major areas: (1) coronary heart disease (CHD), manifested by stable angina, unstable angina, myocardial infarction (MI), heart failure, and coronary death; (2) cerebrovascular disease, manifested by transient ischemia attack and stroke; (3) peripheral vascular disease, manifested by claudication and critical limb ischemia; and (4) aortic atherosclerosis and aortic aneurysm (thoracic and abdominal). CHD remains the leading cause of death for both men and women in the United States. So, it is imperative to identify people at risk of CHD and provide appropriate medical treatment or intervention to prevent serious complications and outcomes including sudden cardiac death. Coronary artery calcification (CAC) is a marker of subclinical coronary artery disease. Therefore, coronary artery calcium score is an important screening method for Coronary artery disease (CAD). In this article, we performed a comprehensive review of current literatures and studies assessing the prognostic value of CAC for future cardiovascular disease (CVD) events. We searched PubMed, MEDLINE, Google Scholar, and Cochrane library. We also reviewed the 2018 American College of Cardiology (ACC)/American Heart Association (AHA) guideline on the assessment of CVD risk. A CAC score of zero corresponds to very low CVD event rates (∼1% per year) and hence a potent negative risk marker. This has been referred to as the ‘power of zero’ and affords the lowest risk of any method of risk calculation. It is now indicated in the 2018 ACC/AHA Cholesterol guidelines to be used to avoid statins for 5–10 years after a score of zero, and then re-assess the patient.
11
Lapina, N. S., A. A. Alekseeva, A. D. Vershinina, N. S. Khruleva, D. S. Zlobina, and L. Yu Koroleva. "Gastrointestinal Bleeding in Patients with Coronary Heart Disease: Preventive Options." Kardiologiia 60, no. 7 (June 19, 2020): 125–35. http://dx.doi.org/10.18087/cardio.2020.7.n942.
Full textAbstract:
Extensive use of antithrombotic drugs (ATD) in patients with ischemic heart disease (IHD), on the one hand, provides a considerable decrease in the risk for development of life-threatening cardiovascular complications but on the other hand, is associated with a risk of gastrointestinal bleedings (GIB), which may develop in 0.5-1.0 % of patients. In such cases, the major measures for prevention of GIB are strict adherence to indications for the ATD treatment, detection and analysis of risk factors for GIB and their elimination as far as feasible. For evaluation of GIB risk in patients with IHD, the PRECISE-DAPT and DAPT, HAS-BLED scales should be used. If the risk factors are non-modifiable the therapeutic tactics for further management of these patients should be strictly individual with determining the nature of damage, degree of a risk for present and possible complications, and the range of required therapeutic and diagnostic measures. The use of ATD requires monitoring of the patient’s condition to timely detect and treat GI complications.
12
Shuper, V. O., S. V. Shuper, I. V. Trefanenko, G. I. Shumko, and T. V. Reva. "Investigation of the Adherence to Prescribed Treatment of the Patients with Coronary Heart Disease." Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 6, no. 5 (October 27, 2021): 263–69. http://dx.doi.org/10.26693/jmbs06.05.263.
Full textAbstract:
The purpose of the study was to investigate the adherence to secondary prevention medications among patients with coronary heart disease and identify factors associated with it. Materials and methods. We examined 40 patients diagnosed with coronary heart disease of more than 50 years old, who were prescribed with optimal medication for 1 year during hospitalization. Patients` adherence was defined according to MMS-8 Morisky values for secondary prevention medications prescribed by doctors. Also, questionnaires about individual reasons of non-compliance and for individual patient`s opinion about importance and usefulness of knowledge according to risk factors of the increase of cardiovascular mortality were designed and proposed to the patients. Simple descriptive statistics were used to elucidate the characteristics of the patient population and results from individual adherence tools. Final score was analyzed and correlation between patients’ data and level of adherence to prescribed treatment were identified. A correlation matrix (using Spearman’s coefficient) was reviewed for any evidence of collinearity. Results and discussion. Our study demonstrated higher level of non-adherence with secondary prevention medications in patients with coronary heart disease (60.0%). This fact can be explained by the socioeconomic reasons, less informative strategies from the medical staff to the patients. Severe regress of adherence was demonstrated after discharge from the hospital due to subjective improvement of the patients` condition with absence of supervision by out-patient specialists. Demographic characteristics of the patients suggested that some non-modified factors can affect compliance with the prescribed treatment. Better adherence was demonstrated by female married patients with higher educational level, with family history about cardiovascular death. Also, too much prescribed medications with difficult regime of usage with non-adequate out-patient supervision may significantly decrease adherence causing development of complications which may lead to re-hospitalizations and cardiovascular death. Our investigation demonstrated also non-complete information of the patients about lifestyle and medical risk factors of the cardiovascular mortality increase. Conclusion. The results of our study can provide useful practical information on the prevalence and severity of non-adherence among patients with coronary heart disease. Analysis of the factors influencing the adherence demonstrated the main reasons from patients and healthcare professionals affecting the level of compliance with the prescribed treatment. The step towards improving adherence can be initiated by the healthcare professional to overcome the patient's concerns about the prescribed medication. It is important to continue personal monitoring of patients by healthcare professionals in the form of regular inspections of intentional and unintentional non-adherence, including factors and reasons that may change and lead to such behavior
13
Korzh, O. M. "CURRENT ASPECTS OF CORONARY HEART DISEASE DIAGNOSIS AND TREATMENT." International Medical Journal, no. 1 (March 5, 2020): 5–10. http://dx.doi.org/10.37436/2308-5274-2020-1-1.
Full textAbstract:
Among the cardiovascular diseases associated with atherosclerosis, chronic coronary heart disease, including angina, is the most common form. It is the myocardium lesion that develops as a result of an imbalance between the coronary circulation and metabolic needs of heart muscle. The presence of angina symptoms often indicates a pronounced narrowing of one or more coronary arteries, but also occurs in non−obstructive arterial impairment and even in normal coronary arteries. Factors of functional damage to the coronary arteries are spasm, temporary platelet aggregation and intravascular thrombosis. Today there are opportunities not only to use the therapy with proven effectiveness, aimed at reducing the risk of complications, including fatal, but also to treat angina (ischemia), which improves the patient's life quality. The drug protocol includes the ones with a proven positive effect on this disease prognosis, which are mandatory if there are no direct contraindications to use, as well as a large group of antianginal or anti−ischemic drugs. The choice of a particular drug or its combinations with other drugs is carried out in accordance with generally accepted recommendations: taking into account the individual approach, the severity of angina, hemodynamic parameters (heart rate and blood pressure, presence of comorbid conditions). If drug therapy is ineffective, the option of coronary myocardial revascularization (percutaneous coronary angioplasty or coronary artery bypass grafting) is considered. Due to the high mortality and morbidity rates of coronary heart disease worldwide, one of the priorities of practical health care is the prevention of diseases caused by atherosclerosis. Key words: coronary heart disease, angina, family physician, prognosis, drug therapy.
14
Eniseeva, E. S., and K. V. Protasov. "Colchicine in patients with coronary heart disease: new possibilities in reduction of the residual inflammatory risk." Siberian Medical Review 6 (2021): 12–21. http://dx.doi.org/10.20333/25000136-2021-6-12-21.
Full textAbstract:
Inflammation plays an important role in atherosclerotic plaque destabilisation and the development of cardiovascular complications. Suppression of its activity in order to reduce residual inflammatory risk in atherosclerotic cardiovascular diseases remains an urgent and unresolved problem to the date. Over the recent years, evidence of the effectiveness of such an approach in secondary prevention of coronary heart disease has been obtained. The purpose of this review was to analyse modern literature on the effect of anti-inflammatory therapy with colchicine on the prognosis of patients with coronary heart disease. The review was carried out using the search for papers published in the PubMed and ClinicalTrials databases within the period from 2007 to 2021. The search was carried out using the keywords «colchicine», «inflammation», «atherosclerosis», «coronary heart disease» and «acute coronary syndrome». The anti-inflammatory and antiatherogenic effects of colchicine are discussed. The paper presents results of studies devoted to the use of colchicine in chronic and acute coronary syndrome, including the key ones LoDoCo2 (2020) and COLCOT (2019) which provided evidence of the effect of the drug on the disease outcome. The issues of safety and prospects of colchicine application in clinical practice for reduction of the residual inflammatory risk in patients with coronary heart disease are addressed.
15
Sayutina, Elena V., Mikhail A. Osadchuk, Boris K. Romanov, Elena M. Tuaeva, Ludmila I. Butorova, Gyulnara O. Dibirova, Natalya V. Kireeva, and Nikolay P. Korzhenkov. "Cardiac rehabilitation and secondary prevention after acute myocardial infarction: a modern view on the problem." Medical Journal of the Russian Federation 27, no. 6 (July 19, 2022): 571–87. http://dx.doi.org/10.17816/0869-2106-2021-27-6-571-587.
Full textAbstract:
Cardiovascular diseases remain a heavy socioeconomic burden in the modern world, claiming up to four million lives annually, including one million of the Russian population. Most often, cardiovascular mortality is associated with chronic coronary heart disease and its complications. Despite the progress in the treatment of acute coronary syndrome in the acute disease phase, the problem of recurrent coronary events and associated adequate rehabilitation remains unresolved. Modern Russian and European recommendations for cardiovascular rehabilitation present the main directions of secondary prevention of myocardial infarction, which summarize the global and Russian evidence-based medicine data on the problem and are based on the principles of phasing, continuity, succession, and multidisciplinary approach to the patient management. This review focuses on the problems and shortcomings of secondary prevention and cardiac rehabilitation at the patient, doctor, and healthcare system levels. In addition, contemporary approaches to their elimination are described. The necessity and importance of individual training and informing patients and the formation of their sustainable commitment to a healthy lifestyle and therapeutic and preventive measures prescribed by modern guidelines on this issue are emphasized.
16
Shved, M. I., and I. O. Yastremska. "PREVENTION OF COMPLICATIONS IN PATIENTS WITH MYOCARDIAL INFARCTION AND CONCOMITANT METABOLIC SYNDROME." Актуальні проблеми сучасної медицини: Вісник Української медичної стоматологічної академії 20, no. 4 (December 30, 2020): 101–7. http://dx.doi.org/10.31718/2077-1096.20.4.101.
Full textAbstract:
In Ukraine, coronary heart disease is still occupying the first place in the structure of the causes of death and primary disability (22.8%), and the incidence of myocardial infarction among people of working age is 48.9 per 100 thousand. The aim of this study was to increase the effectiveness of the treatment and prevention of complications in patients with acute coronary syndrome (myocardial infarction) and concomitant metabolic syndrome by including L-carnitine and L-arginine to the integrated therapy. The study involved 71 patients with acute coronary syndrome (ACS) with ST-segment elevation and concomitant metabolic syndrome. Among the 37 individuals who were prescribed a course of cytoprotective therapy additional to the standard drug therapy according to the protocol of the Ministry of Health, formed a test group. The control group consisted of 34 patients who only received standard protocol treatment with corticosteroids (MI). The diagnosis of acute myocardial infarction was verified according to the ESC recommendations (2017). Diagnosis of metabolic syndrome (MS) was established based on the recommendations of the International Diabetes Federation (IDF, 2016). It was found that due to the integrated therapy including L-arginine and L-carnitine, the patients with ACS (MI) and concomitant MS achieved a significant improvement in central cardiohemodynamics and the restoration of vascular endothelial function that was often accompanied by the following complications of corticosteroids (MI) as reperfusion arrhythmias and blockades and acute heart (left ventricular) failure. The patients with acute myocardial infarction and concomitant MS demonstrated pronounced deterioration of morpho-functional parameters of the heart, and namely the development of its post infarction remodelling with subsequent impairments of systolic and diastolic heart function and the development of heart failure and endothelial vascular dysfunction. A mixture of L-arginine and L-carnitine added to the standard therapy significantly reduces the incidence and severity of complications of acute MI such as reperfusion arrhythmias and acute left ventricular failure.
17
Dzeshka, M. S., A. A. Chernyak, V. A. Snezhitskiy, A. V. Yanushka, A. V. Maksimchik, and H. A. Madzekina. "PERCUTANEOUS CORONARY INTERVENTIONS – CURRENT STATE OF DEVELOPMENT: PREVENTION OF COMPLICATIONS AND FUTURE PERSPECTIVES." Journal of the Grodno State Medical University 18, no. 6 (December 31, 2020): 655–63. http://dx.doi.org/10.25298/2221-8785-2020-18-6-655-663.
Full textAbstract:
Antiplatelet therapy is an essential part of cardiovascular prevention in patients with coronary heart disease (CHD). Damage to the vascular wall caused by percutaneous coronary intervention (PCI) is accompanied by extensive platelet activation followed by inevitable risk of thrombosis within implanted stent both in patients with acute coronary syndromes and in those with chronic CHD especially before endothelization is completed. Effective prevention of ischaemic complications necessitates dual antiplatelet therapy including its combination with anticoagulation therapy. Duration of the combined therapy is determined by clinical scenario as well as balancing the risk of ischaemic and haemorrhagic events. Risk assessment is an integral part of patient management. Technological advances in the field of coronary interventions aim to assess atherosclerotic lesions precisely in terms of requirement of revascularization, minimize damage to the vascular wall, promote endothelization, and allow shortening of antithrombotic therapy without losing long-term effectiveness of PCI and increasing the rate of stent thrombosis. The current review discusses prevention of complications after PCI with focus on antithrombotic therapy as well as future perspectives of PCI.
18
Efimova, Nataliya Yu, Vladimir I. Chernov, Irina Yu Efimova, Shamil D. Akhmedov, and Yuri B. Lishmanov. "Use of 99mTc-HMPAO in Evaluating the Results of Cerebral Hypoperfusion Prevention in the Patients with Coronary Heart Disease after Coronary Artery Bypass Grafting." Advanced Materials Research 1084 (January 2015): 506–10. http://dx.doi.org/10.4028/www.scientific.net/amr.1084.506.
Full textAbstract:
The purpose of this study is to research the use of the radiopharmaceutical99mTc-HMPAO in the evaluation of drug prevention of cerebral complications in patients with coronary heart disease after coronary artery bypass grafting (CABG) performed with cardiopulmonary bypass (CPB). The study included 30 patients, in whom surgical revascularization was performed with CPB. 11 patients in this group were prescribed instenon. All the patients underwent brain tomoscintigraphy with99mTc-HMPAO and neuropsychological testing before CABG and 10-15 days after it. The results showed that99mTc-HMPAO is useful radiopharmaceutical for evaluation of cerebral complications in patients after CABG. Thus, coronary artery bypass grafting using CPB can be complicated by the deterioration of cerebral perfusion and cognitive dysfunction, while preventive medication with instenon can prevent or significantly reduce the violations of cerebral hemodynamics and neuropsychological status of the patients.
19
Cherniy, V. I., and Y. V. Kurylenko. "DIFFERENTIATED APPROACH TO PREVENTION AND TREATMENT OF ACUTE LEFT VENTRICULAR FAILURE IN PATIENTS WHO UNDERWENT CORONARY ARTERY BYPASS GRAFT SURGERY WITH CARDIOPULMONARY BYPASS." Клінічна та профілактична медицина 2, no. 20 (May 19, 2022): 16–25. http://dx.doi.org/10.31612/2616-4868.2(20).2022.02.
Full textAbstract:
Introduction. Coronary heart disease (CHD) is the accumulation of atherosclerotic plaques in the blood vessels that supply the heart with oxygen and nutrients. Coronary artery bypass grafting (CABG) is a strategy for myocardial revascularization that is indicated for patients with three or more coronary artery demage, high SYNTAX, diabetes, and left ventricular systolic dysfunction. Despite the tremendous development of equipment, surgical and anesthesia techniques, in the perioperative period, there are still complications. The most formidable complication after such an operation of CABG with cardiopulmonary bypass (CPB) is the development of acute left ventricular failure (ALVF).
The aim. To study the effectiveness of the principles of a differentiated approach to the prevention and correction of ALVF in patients who underwent surgery - CABG with CPB.
Materials and methods. 500 cardiac surgery patients with coronary heart disease were operated on at SIS “Research and Practical Center of Preventive and Clinical Medicine” SAD. In all the cases, coronary artery bypass grafting was performed using cardiopulmonary bypass. In order to verify the principles of a differentiated approach to the correction and prevention of ALVF, the study was divided into three stages. At the first stage, the problem of the metabolic component of ALVF correction was studied (60 patients). On the second - the problem of diagnosis and correction of hypophosphatemia (60 patients with preoperative hypophosphatemia). On the third - diagnostic properties of the innovative method "Phasagraphy" (80 patients).
Results. The introduction of a combination of levocarnitine and arginine, fructose-1,6-diphosphate - in case of hypophosphatemia, in the treatment of ALVF can reduce the recovery time of hemodynamics and reduce the total dose of inotropic drug (dobutamine) needed to achieve stabilization. The LF/HF indicator reliably reflects the ratio of sympathetic and parasympathetic parts of the autonomic nervous system, responds to disturbances and restoration of hemodynamics. The βT index of the phasagraphy method is related to clinical data on myocardial status.
Conclusions. To prevent the development of ALVF in patients with coronary heart disease requires a differentiated approach: perioperative diagnosis of hypophosphatemia and its correction. In the case of ALVF after CABG surgery in patients with coronary heart disease to stabilize hemodynamics, the use of inotropic support with dobutamine and metabolic support with a combination of levocarnitine and arginine. As monitoring of myocardial condition it is advisable to use LF/HF indicator of variation pulsometry and βT method of phasagraphy.
20
Chazova, I. Ye, S. A. Tyulyandin, M. V. Vitsenia, M. G. Poltavskaya, M. Yu Gilyarov, T. V. Martynyuk, A. G. Ovchinnikov, et al. "Clinical Manual for Diagnosis, Prevention and Treatment of Cardiovascular Complications of Cancer Therapy. Parts II-V." Systemic Hypertension 14, no. 4 (December 15, 2017): 6–19. http://dx.doi.org/10.26442/sg29199.
Full textAbstract:
Advances in treatment have led to improved survival of patients with cancer but have also resulted in untoward side effects associated with treatment. Cardiovascular diseases are one of the most frequent of these side effects. Myocardial dysfunction and heart failure, myocardial ischaemia, arrhythmias, arterial hypertension, thromboembolic disease and other cardiovascular complications can interfere with the efficacy of treatment, decrease quality of life, or impact the actual survival of the patient with cancer. This manual discusses concepts for timely diagnosis, intervention, and surveillance of patients treated with cardiotoxic cancer therapies. In this second part оf manual we discuss the diagnostic, prevention and treatment aspects of cancer therapy-related coronary artery disease, arterial hypertension, arrhythmias and pulmonary hypertension.
21
Gramley, Felix, and Andreas Goette. "Implantable Cardioverter–Defibrillators for Primary Prevention of Sudden Cardiac Death." European Cardiology Review 6, no. 3 (2010): 92. http://dx.doi.org/10.15420/ecr.2010.6.3.92.
Full textAbstract:
Sudden cardiac death (SCD) remains a major cause of death in the industrialised world. Implantable cardioverter–defibrillators (ICDs) have been shown to be an effective therapy option for the primary prevention of SCD in patients at high risk of SCD. This review will discuss adequate risk stratification in various disease states, such as coronary artery disease, ischaemic and non-ischaemic cardiomyopathies (dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), channelopathies (Brugada syndrome, long- QT syndrome, short-QT syndrome, catecholaminergic polymorphic ventricular tachycardia) and congenital heart diseases, to identify patients at high risk of SCD and selection criteria for ICD therapy. The most important clinical primary prevention trials will be highlighted. Finally, complications of device therapy and quality of life issues will be addressed.
22
Gilyarov, M. Yu, E. V. Konstantinova, E. A. Koroleva, A. G. Popova, E. E. Popov, D. A. Anichkov, N. I. Raschetnova, and A. V. Svet. "Coronary heart disease and depressive disorders, pathogenesis and actual features of the relationship." Meditsinskiy sovet = Medical Council, no. 14 (August 10, 2022): 16–22. http://dx.doi.org/10.21518/2079-701x-2022-16-14-16-22.
Full textAbstract:
In the conditions of the existing pandemic, that affects both the physical and psychological health of people, it can be predicted with a high degree of probability an outbreak in mental disorders and stress-associated mental illnesses, including depression. The problem of the relationship between depression and cardiac diseases, in particular coronary heart disease (CHD), has been studied by native and foreign scientists for several decades. Various mechanisms have been found and continue to be studied, indicating that the presence of depression can affect more or less on the course of coronary heart disease and even become a predictor of new cardiac events. Dysfunction of the autonomic nervous system with changes in heart rate variability, hyperactivity of the hypothalamic-pituitary-adrenal axis and associated hypercortisolemia, disorders of serotonergic signal transmission pathways, high aggregation response and increased platelet activity, continuous increase of proinflammatory cytokines ((IL17A, IL6, TNFa and IL12p70) in patients’ plasma – such mechanisms probably underlie the correlation between depression and an increased risk of cardiovascular complications and cardiac death. The review includes some features of depression and its influence on various forms of coronary heart disease, particularly in different age and gender groups. In view of the ongoing COVID-19 pandemic, this theme seems to be relevant and requires targeted study. Probably it is necessary to conduct clinical researches, to create registers for a detailed assessment of the mutual influence of depression and coronary heart disease in existing conditions. Perhaps, the results of such work will contribute not only to the early detection and treatment of depression, but also to the development of new ways in primary and secondary prevention of coronary heart disease and its acute forms.
23
Turovets, M. I., P. V. Mozgovoy, A. V. Ekstrem, S. M. Slakhter, and A. V. Lopushkov. "PREVENTION OF SHORT-TERM COMPLICATIONS FOR OFF-PUMP CORONARY ARTERY BYPASS GRAFTING IN PATIENTS WITH DIABETES MELLITUS." Journal of Volgograd State Medical University 75, no. 3 (September 30, 2020): 39–45. http://dx.doi.org/10.19163/1994-9480-2020-3(75)-39-45.
Full textAbstract:
Diabetes mellitus is an independent risk factor for the development of early postoperative complications in coronary artery bypass grafting without cardiopulmonary bypass (off-pump CABG). A comparative analysis of early postoperative complications for off-pump CABG in patients with diabetes mellitus was made. A randomized study of the results of surgical treatment of patients with coronary heart disease who underwent coronary artery bypass grafting of 2 or more branches of the coronary arteries without the use of cardiopulmonary bypass included 191 patients. In patients of the main group (n = 32), the comorbid background was complicated by diabetes; in patients in the control group (n = 159), this disease was not detected. For statistical processing of the obtained data, nonparametric criteria were used (Fisher test and relative risk (RR) with a 95% confidence interval (CI)). It is proved that in patients of the main group (with diabetes) the relative risk of developing postoperative complications (acute myocardial infarction, pneumonia, acute renal failure, multiple organ failure syndrome, etc.) is significantly higher than in patients in the control group (RR = 1.36–4.97). The use of combined anesthesia (with prolonged thoracic epidural analgesia) allowed patients of both groups to significantly reduce the risk of developing clinically significant complications (RR = 0.26–0.78). Performing off-pump CABG in patients with diabetes is associated with a significant increase in the risk of postoperative complications, and the use of combined anesthesia effectively reduces the risk of their development in patients of this category.
24
Panov, A. V., E. V. Kuleshova, N. L. Lokhovinina, M. Z. Alugishvili, I. T. Abesadze, I. V. Titenkov, and Yu A. Kudaev. "Assessment of cardiovascular risk and prevention of complications in non-cardiac surgery in patients with coronary heart disease." "Arterial’naya Gipertenziya" ("Arterial Hypertension") 26, no. 6 (January 18, 2021): 629–39. http://dx.doi.org/10.18705/1607-419x-2020-26-6-629-639.
Full textAbstract:
The incidence of cardiovascular complications in non-cardiac surgery is about 3 %. The review presents the data on the assessment of cardiovascular risk (CVR) in non-cardiac surgery. The algorithm of decisionmaking considers the functional state of the patient and the category of CVR of the upcoming surgery. Functional testing is not indicated for patients with low CVR. Stress tests should be considered in high-risk patients if the test results may change the perioperative drug therapy, the method of anesthesia, or the surgical approach. Routine coronary revascularization does not reduce perioperative risks and is used for special indications. Percutaneous coronary intervention and associated dual antiplatelet therapy may delay the timing of non-cardiac operations. Perioperative drug therapy (beta-blockers, aspirin, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and statins) should be prescribed taking into account the individual risk of the patient.
25
Roytberg, G. E., and I. D. Slastnikova. "Modern Approaches to Optimal Antithrombotic Therapy for Stable Ischemic Heart Disease." Russian Archives of Internal Medicine 10, no. 5 (October 9, 2020): 348–56. http://dx.doi.org/10.20514/2226-6704-2020-10-5-348-356.
Full textAbstract:
The article highlights the practical aspects of the use of antithrombotic therapy in patients with stable (chronic) coronary artery disease (САD). The САD verification using modern functional and anatomical diagnostic methods are considered. Patients with stable САD represent a heterogeneous group, having various clinical scenarios. Information is provided on the main risk factors for ischemic and hemorrhagic complications that determine the choice of optimal antithrombotic therapy regimens. Modern views on the monotherapy and clopidogrel in САD are presented. The data of the largest international studies CHARISMA and PEGASUS-TIMI 54 on the use of double antiplatelet therapy in patients with stable IHD reflected in modern guidelines are highlighted. Features of new antiplatelet agents (prasugrel and ticagrelol) are described. Based on the results of the COMPASS study, indications for the administration of small doses of rivaroxaban in combination with aspirin for the secondary prevention of cardiovascular complications in patients with stable manifestations of atherosclerosis with a low risk of bleeding are considered. The use of antithrombotic therapy is associated with an increased risk of bleeding and particularly with gastrointestinal bleeding. The information on the use of drugs for the prevention of gastrointestinal bleeding is provided.Antithrombotic therapy can reduce the risk of complications associated with atherothrombosis, however, to improve prognosis a multipurpose intervention is required, including correction of risk factors and the use of drugs from different groups with proven effectiveness. Optimal medical therapy, including antithrombotic drugs, is vital for patients with САD and can successfully prevent adverse outcomes.
26
Yavelov, I. S. "Elderly patient with atrial fibrillation and coronary risks." Aterotromboz = Atherothrombosis, no. 1 (July 13, 2021): 51–57. http://dx.doi.org/10.21518/2307-1109-2021-11-1-51-57.
Full textAbstract:
The incidence of atrial fibrillation (AF) and coronary heart disease (CHD) increases with age. Obviously, this is largely due to the coincidence of risk factors for the occurrence and progression of AF and risk factors for the occurrence and progression of atherosclerosis, including coronary atherosclerosis. Vitamin K antagonists, which are necessary for stroke prevention in patients with AF, are also reported to be able to prevent thrombotic complications of coronary atherosclerosis. No studies specifically designed to compare direct oral anticoagulants (DOACs) and vitamin K antagonists in the prevention of coronary thrombosis have been conducted, However, analysis of the results of randomized controlled trials ARISTOTLE, AUGUSTUS, PIONEER AF-PCI, REDUAL PCI, RE-LY and ROCKET AF indicates that in general DOACs are not inferior to warfarin in the ability to protect patients with AF from myocardial infarction and stent thrombosis. Accordingly, in stable patients with non-valvular AF (who have not suffered an acute coronary syndrome in the next 1 year or planned coronary stenting in the next 6 months) they can be used as monotherapy, without simultaneous administration of antiaggregants. Taking into account the data obtained in patients with sinus rhythm who recently had acute coronary syndrome in the randomized controlled trial ATLAS-ACS 2, as well as with stable atherosclerotic disease in the randomized controlled trial COMPASS, the greatest evidence base in the prevention of coronary complications has been accumulated with rivaroxaban. At the same time, the results of the COMPASS study, as well as analysis of daily medical practice indicate its additional benefits in patients with peripheral atherosclerosis.
27
Tilz, Roland R., Charlotte Eitel, Evgeny Lyan, Kivanc Yalin, Spyridon Liosis, Julia Vogler, Ben Brueggemann, et al. "Preventive Ventricular Tachycardia Ablation in Patients with Ischaemic Cardiomyopathy: Meta-analysis of Randomised Trials." Arrhythmia & Electrophysiology Review 8, no. 3 (August 9, 2019): 173–79. http://dx.doi.org/10.15420/aer.2019.31.3.
Full textAbstract:
Catheter ablation of ventricular tachycardia (VT) aims to treat the underlying arrhythmia substrate to prevent ICD therapies. The aim of this meta-analysis was to assess the safety and efficacy of VT ablation prior to or at the time of secondary prevention ICD implantation in patients with coronary artery disease, as compared with deferred VT ablation. Based on a systematic literature search, three randomised trials were considered eligible for inclusion in this analysis, and data on the number of patients with appropriate ICD shocks, appropriate ICD therapy, arrhythmic storm, death and major complications were extracted from each study. On pooled analysis, there was a significant reduction of appropriate ICD shocks (OR 2.58; 95% CI [1.54–4.34]; p<0.001) and appropriate ICD therapies (OR 2.04; 95% CI [1.15–3.61]; p=0.015) in patients undergoing VT ablation at the time of ICD implantation without significant differences with respect to complications (OR 1.39; 95% CI [0.43–4.51]; p=0.581). Mortality did not differ between both groups (OR 1.30; 95% CI [0.60–2.45]; p=0.422). Preventive catheter ablation of VT in patients with coronary heart disease at the time of secondary prevention ICD implantation results in a significant reduction of appropriate ICD shocks and any appropriate ICD therapy compared with patients without or with deferred VT ablation. No significant difference with respect to complications or mortality was observed between both treatment strategies.
28
Kovacevic-Kostic, Natasa, Radmila Karan, Mile Vranes, Dejan Markovic, Milos Velinovic, and Zivan Maksimovic. "Preoperative preparation of vascular patients undergoing nonvascular surgery." Acta chirurgica Iugoslavica 58, no. 2 (2011): 55–61. http://dx.doi.org/10.2298/aci1102055k.
Full textAbstract:
Patients with vascular diseases mainly caused by atherosclerosis, that are undergoing nonvascular surgery, often have co-existing conditions which affect their cardiovascular system. Cardiovascular complications are among the most common perioperative complications including respiratory complications and infections. These include coronary disease, hypertension, heart insufficiency, pulmonary hypertension, and renovascular hypertension, among others. Preoperative preparation must include the use of ?blocker therapy, antihypertensive, antithrombotic and antilipogenic therapy. Electrocardiogram (ECG) and trans-thoracic echocardiography are the minimum preoperative diagnostic evaluations that should be performed, because complications may arise even in patients without prior cardiovascular symptomatology. Venous diseases are the most common contemporary diseases affecting people of all age groups and races. Invasive-diagnostic-therapeutic procedures may cause lesions of venous endothelium, hence perioperative prevention of deep vein thrombosis (DVT) with the use of heparin or low-molecular -weight heparin (LMWH) should be undertaken.
29
Ştefan, Ramona Maria, Cristina Niţă, Anca Crăciun, Adriana Rusu, and Nicolae Hâncu. "Prevention Of Coronary Heart Disease And Stroke Complications In Type 2 Diabetes Mellitus: An Observational, Prospective Study." Romanian Journal of Diabetes Nutrition and Metabolic Diseases 22, no. 2 (June 1, 2015): 175–85. http://dx.doi.org/10.1515/rjdnmd-2015-0022.
Full textAbstract:
AbstractBackground and Aims: We assessed the effect of intensive therapy on modifiable cardiovascular (CV) risk factors and CV risk as compared to conventional therapy in patients with newly diagnosed type 2 diabetes mellitus (T2DM).Material and Methods: This was an observational, prospective study, conducted in Romania. During 1-year follow-up period the enrolled participants received either multi-factorial pharmacotherapy associated with intensive therapeutic education (Intensive group), or conventional therapy (Control group). Current analysis included data (anthropometric measurements, blood pressure and biochemical parameters) recorded at months (M) 0, 6 and 12. CV risk was calculated at M1 and M12 using the UK Prospective Diabetes Study Risk Engine.Results: 138 patients aged 57.02±10.05 years were included in this analysis (69 in each group). At M6 and M12 a significant improvement of the majority of the modifiable risk factors in the Intensive group compared to the Control group was observed. At M12, coronary heart disease (CHD)/fatal-CHD risks were significantly lower in the Intensive (7.5%/3.1%) than in the Control (17.95%/10.3%) group (p<0.05). A similar trend was observed for the stroke/fatal-stroke risks.Conclusions: CHD/fatal-CHD and stroke/fatal-stroke risk burden decreased in newly diagnosed diabetic patients following multi-factorial pharmacotherapy association with intensive lifestyle changes during 1-year follow-up.
30
Verma, Raunak, Shashank Tandon, and Mr Vinayak. "Heart Disease Prediction using Machine Learning." International Journal for Research in Applied Science and Engineering Technology 10, no. 5 (May 31, 2022): 1872–76. http://dx.doi.org/10.22214/ijraset.2022.42687.
Full textAbstract:
Abstract: The term "heart disease" refers to any heart disease or condition that can cause heart problems. Cardiovascular disease (CVD) is the leading cause of death worldwide, taking many lives each year. CVD is a group of cardiovascular diseases and includes heart disease, cerebrovascular disease, rheumatic heart disease and other conditions. According to the World Health Organization (WHO), more than 17.9 million people worldwide die each year from coronary heart disease. If we take the example of India, every year the number of deaths due to heart disease has increased. Studies show that, from 2014 to 2019 the number of deaths from heart disease increased by 53%. Many threatening factors such as personal and work habits and genetic predisposition are major causes of heart disease. A variety of harmful habits such as smoking, alcohol and caffeine overdose, stress, and inactivity as well as other physical factors such as obesity, high blood pressure, high blood cholesterol, and pre-existing heart conditions are the main causes of heart disease. Over time, these harmful substances cause changes in the heart and blood vessels that can lead to heart attacks and strokes. Therefore, prevention of heart disease is very important to prevent these dangerous events and other potential complications of heart disease. Machine learning is a flexible part of AI that helps predict heart disease. In this research work, we will use the UCI database with 14 attributes to predict heart disease. The main goal of this study is to use ML algorithms to improve the heart disease prediction system and to more accurately predict these diseases in patients, thereby reducing the number of deaths by alerting patients. Keywords: Heart Diseases, Classification Algorithms, Machine Learning, UCI dataset.
31
Parvin, Rehana, Kazi Jahangir Hossain, Tamanna Zahur, Md Rizwanul Karim, ANM Shamsul Islam, and Baizid Khoorshid Riaz. "Knowledge of the Patients Family Member about Risk Factors and Complications of Coronary Heart Disease." Journal of Medicine 17, no. 2 (October 23, 2016): 84–90. http://dx.doi.org/10.3329/jom.v17i2.30070.
Full textAbstract:
Objective: To assess knowledge about risk factors and complication of coronary heart disease (CHD).Method: It was a cross-sectional type of study and research participants were one of the family members of the patient suffering from coronary heart disease. The sample population and unit of sample were households. A total of 147 participants were selected from Inpatient Department of the National Institute of Cardio-Vascular Disease, Sher-e-Bangla Nagar, Dhaka from January 2013 to July 2013 following purposive method of sampling on the basis of defined selection criteria. The research instrument was a pre-tested face-to-face interviewer questionnaire. Knowledge level of the respondents was assessed using Likert type of scale incorporate in the questionnaire.Results: Most of the research participants (95.2%, n=140) were educated and only 4.8% (n=07) found illiterate. In profession, 29.9% (n=44) of the respondents were housewife, 36.1% (n=53) service holder, 22.4% (n=24) businessmen and 11.6% (n=17) students. Their average monthly income was Tk. 9149±108 and their family income was Tk. 3448±7 in average. The mean age of the respondents was 33.1±6.8 years of which 76.9% (n=113) married and rest of them (23.1%, n=34) unmarried. Among the respondents, 50.3(n=74) were male and 49.7% (n=73) female respectively. The level of knowledge of the respondents about risk factors and complication of coronary heart disease on the basis of gender, education and occupation was assessed. Of them, 75.5% (n=111) had poor knowledge about risk factors and complication of coronary heart disease, 24.5% (n=36) satisfactory knowledge and none of them had good knowledge about it which was significantly associated with the level of education, occupational and monthly income status of the respondents.Conclusion: An individual can modify or avoid many risk factors to prevent CHD or minimize the complication of CHD except age and genetic factors. However, need based health education and behavioral change intervention programs among the risk populations (target populations) and to ensure easy access in public healthcare facilities may be the most important applicable ways to control and/or prevention of CHD in Bangladesh.J MEDICINE July 2016; 17 (2) : 84-90
32
Dreval, A. K. "Prevention and treatment of diabetic microangiopathy: A lecture." Problems of Endocrinology 41, no. 6 (December 15, 1995): 29–34. http://dx.doi.org/10.14341/probl11491.
Full textAbstract:
One of the main complications leading to high disability and mortality in patients with diabetes mellitus is atherosclerotic vascular disease (diabetic macroangiopathy). At the same time, the frequency of atherosclerosis among patients with diabetes mellitus is significantly affected by the so-called risk factors for atherosclerosis. In particular, the incidence of atherosclerosis among the general population and among diabetics increases with increased levels of cholesterol (cholesterol) in the blood, blood pressure, smoking and obesity. However, in patients with diabetes mellitus, mortality, for example, from coronary heart disease increases by 3 times against any of the known risk factors. But even without risk factors, the frequency of atherosclerotic vascular damage in patients with diabetes is much higher than in non-diabetic patients, i.e. diabetes in itself is a risk factor for atherosclerosis.
33
Sharma, Nikhil, and Nitin Khuller. "Periodontal Vaccine: A New Paradigm for Prevention of Periodontal Diseases." Journal of Oral Health and Community Dentistry 4, Spl (2010): 23–28. http://dx.doi.org/10.5005/johcd-4-spl-23.
Full textAbstract:
ABSTRACT Vaccination is a process that induces specific immune resistance to a bacterial or viral infectious disease. Vaccines have prevented several infectious diseases for many years, and are still being investigated. In late eighteenth century, Edward Jenner developed and established the principle of vaccination using the cross protection conferred by cowpox virus, which is non pathogenic in humans. Regarding a vaccine against the periodontal disease, the complexity of the periodontopathic bacteria might be a problem in determination of Antigens. Among some 300 species of bacteria involved in subgingival plaque, 5-7 species have been implicated in the etiology of periodontitis but one or two species; P.gingivalis or B. forsythus might play an important role as primary pathogens. Vaccination accomplished can be active immunization, passive immunization or DNA vaccination, made from the antigenic epitopes in periodontopathic bacteria. In light of the increasing evidence that periodontitis significantly increases risk for potentially fatal diseases such as coronary heart disease, stroke and complications from diabetes mellitus a successful vaccine for periodontitis could have health benefits far exceeding the prevention of periodontitis.
34
Popovic-Pejicic, Snjezana, Ljiljana Todorovic-Djilas, and Pavle Pantelinac. "The role of autonomic cardiovascular neuropathy in pathogenesis of ischemic heart disease in patients with diabetes mellitus." Medical review 59, no. 3-4 (2006): 118–23. http://dx.doi.org/10.2298/mpns0604118p.
Full textAbstract:
Introduction. Diabetes is strongly associated with macrovascular complications, among which ischemic heart disease is the major cause of mortality. Autonomic neuropathy increases the risk of complications, which calls for an early diagnosis. The aim of this study was to determine both presence and extent of cardiac autonomic neuropathy, in regard to the type of diabetes mellitus, as well as its correlation with coronary disease and major cardiovascular risk factors. Material and methods. We have examined 90 subjects, classified into three groups, with 30 patients each: those with type 1 diabetes, type 2 diabetes and control group of healthy subjects. All patients underwent cardiovascular tests (Valsalva maneuver, deep breathing test, response to standing, blood pressure response to standing sustained, handgrip test), electrocardiogram, treadmill exercise test and filled out a questionnaire referring to major cardiovascular risk factors: smoking, obesity, hypertension, and dyslipidemia. Results. Our results showed that cardiovascular autonomic neuropathy was more frequent in type 2 diabetes, manifesting as autonomic neuropathy. In patients with autonomic neuropathy, regardless of the type of diabetes, the treadmill test was positive, i.e. strongly correlating with coronary disease. In regard to coronary disease risk factors, the most frequent correlation was found for obesity and hypertension. Discussion Cardiovascular autonomic neuropathy is considered to be the principal cause of arteriosclerosis and coronary disease. Our results showed that the occurrence of cardiovascular autonomic neuropathy increases the risk of coronary disease due to dysfunction of autonomic nervous system. Conclusions. Cardiovascular autonomic neuropathy is a common complication of diabetes that significantly correlates with coronary disease. Early diagnosis of cardiovascular autonomic neuropathy points to increased cardiovascular risk, providing a basis for preventive and therapeutic measures. .
35
Kozlov, I. A., A. M. Ovezov, and A. A. Pivovarova. "Reduction of risk of perioperative complications in case of cardiac comorbidity." Messenger of ANESTHESIOLOGY AND RESUSCITATION 17, no. 2 (May 15, 2020): 38–48. http://dx.doi.org/10.21292/2078-5658-2020-17-2-38-48.
Full textAbstract:
The objective: based on the published data to describe the conceptual issues of the problem of perioperative cardiac complications in non-cardiac surgery.Results: changes made to international guidelines over the past 3–4 years based on evidence-based studies and meta-analyzes have been analyzed. The article presents data on the etiopathogenesis of various postoperative cardiac complications, assessment of their risk based on the evaluation of functional activities of patients, cardiac risk indices, and modern biomarkers (B-type natriuretic peptides, cardiospecific troponins). The contemporary recommendations on adjuvant pharmacological cardioprotection and rational pharmacotherapy in the perioperative period are analyzed. The article describes specific parameters of diagnostic, treatment and prevention tactics in patients with coronary heart disease, hypertension, chronic heart failure, heart defects, and implanted electronic devices. It concludes that the implementation of the comprehensive strategy aimed at the reduction of risk of pulmonary complications should ensure the decrease in their frequency and mortality due to them.
36
Abdullaev, A. A., R. M. Gafurova, U. A. Islamova, R. G. Khabchabov, E. R. Makhmudova, and M. A. Dzhanbulatov. "Сhanges in the quality of life of patients undergoing coronary stenting and with concomitant pathology." EMERGENCY MEDICAL CARE 22, no. 3 (September 30, 2021): 32–37. http://dx.doi.org/10.24884/2072-6716-2021-22-3-32-37.
Full textAbstract:
Goal — was to assess the quality of life of patients with coronary heart disease, concomitant type II diabetes mellitus and arterial hypertension at 2 years after coronary stenting. Material and methods. The study included 103 patients aged 44 to 67 years. Clinical and laboratory results were assessed after stenting of the coronary arteries, 2 years later in an outpatient setting. The patients were divided into two groups: the 1st group included 54 patients with ischemic heart disease, angina pectoris III–IV f.c. in combination with arterial hypertension; in the 2nd group — 49 patients with ischemic heart disease, angina pectoris III–IV f.k. in combination with arterial hypertension and type II diabetes mellitus. The study was carried out in accordance with Good Clinical Practice and Declaration of Helsinki principles. The study protocol was approved by the Ethics Committees of all participating clinical centers. Written informed consent was obtained from all participants prior to enrollment.Results. In our study, 103 patients with ischemic heart disease and angina pectoris III–IV f.c. Within 2 years after coronary artery stenting, 33 cases of myocardial infarction (32.0%) were registered. The quality of life improved to stable exertional angina pectoris I–II f.k. 34 patients (33.0%). At the same time, 39.8% did not change their quality of life. Myocardial infarction in the group with angina pectoris III–IV f.k. and arterial hypertension, developed in 12 (22.2%) patients, and in the group with angina pectoris III–IV f.c. and arterial hypertension + type II diabetes mellitus were registered in 21 (42.8%) patients, which is almost twice as high as in group 1, the same for improving the quality of life. That is, despite the stenting of the coronary arteries, the high incidence of complications in the form of myocardial infarction can be explained by a combination of concomitant diseases, in the form of arterial hypertension + type II diabetes mellitus. We are confident that type II diabetes mellitus has a greater impact on the quality of life and complications in patients who have undergone coronary stenting. At the same time, the risk of complications decreases with adequate control of arterial hypertension and type II diabetes mellitus — the transition of angina pectoris III–IV to I–II f.c. characterized by a significant improvement at p-0.0034; odds ratio 0.50; the confidence interval is 0.31–0.80. Conclusion. The improvement in the quality of life in patients with coronary heart disease and arterial hypertension after stenting of the coronary arteries in the long-term period is twice as good as in patients with coronary heart disease and arterial hypertension + type II diabetes mellitus. Arterial hypertension is a serious but manageable risk factor for the development of macrovascular and microvascular complications. The study demonstrated the effectiveness of correcting only arterial hypertension in terms of preventing cardiovascular and microvascular complications than the combination of arterial hypertension and type II diabetes mellitus, which significantly worsen the prognosis of the disease in patients with coronary artery disease after coronary artery stenting. This is reflected in the recommendations for stratification of the risk of arterial hypertension and type II diabetes mellitus.
37
Tsvetkova, O. A., and O. O. Voronkova. "Safety and efficacy of acetylsalicylic acid in the secondary prevention of cardiovascular diseases in combination with comorbid diseases. COVID-19 treatment options." Meditsinskiy sovet = Medical Council, no. 12 (September 19, 2021): 8–16. http://dx.doi.org/10.21518/2079-701x-2021-12-8-16.
Full textAbstract:
Secondary prevention of cardiovascular disease with aspirin is a very important issue. Аcetylsalicylic acid ensures the prevention of premature death, inhibition of progression and the achievement of partial regression of coronary atherosclerosis, prevention of clinical complications and exacerbations of the disease, reduction of the number of cases and the duration of hospitalization. The most promising direction of modern cardiology is considered to be the prevention of cardiovascular diseases (CVD) and their complications (CVD). This is due to two factors: an increase in the life expectancy of the world’s population as a whole and the persistent leadership of coronary heart disease and brain stroke as the leading causes of death, and disability. The pathogenetic aspects of the administration of acetylsalicylic acid are discussed. The most common dosage form of low-dose (ld) preparations of acetylsalicylic acid (ASA) for preventive use is an intestinal-soluble tablet — 80.6% in the structure of ldASK preparations. Low-dose ASK preparations are mainly presented (84.4%) in the form of monopreparations containing only ASA as the active substance, most often at a dose of 100 mg. However, the side effects of aspirin limit drug intake. This is also due to the high frequency of comorbid diseases such as bronchial asthma and stomach ulcer. The article discusses the issue of prescribing acetylsalicylic acid and the possibility of treating patients with concomitant bronchial asthma, gastric ulcer and obesity. The prevalence of gastroduodenal lesions was significantly lower with intestinal-coated ASA than with buffered acetylsalicylic acid. It was demonstrated that endoscopic lesions of the gastroduodenal mucosa were significantly less likely when using intestinal-coated ASA (100 mg / day) than when using conventional аcetylsalicylic acid, and the assessment of the lesion when using intestinalcoated ASA was similar to the assessment of placebo without аcetylsalicylic acid. In addition, the issue of the possibility of including аcetylsalicylic acid in the treatment regimen for COVID 19 is being discussed.
38
Franco, Vivian I., Jacqueline M. Henkel, Tracie L. Miller, and Steven E. Lipshultz. "Cardiovascular Effects in Childhood Cancer Survivors Treated with Anthracyclines." Cardiology Research and Practice 2011 (2011): 1–13. http://dx.doi.org/10.4061/2011/134679.
Full textAbstract:
Anthracyclines are commonly used to treat childhood leukemias and lymphomas, as well as other malignancies, leading to a growing population of long-term childhood cancer survivors. However, their use is limited by cardiotoxicity, increasing survivors' vulnerability to treatment-related complications that can markedly affect their quality of life. Survivors are more likely to suffer from heart failure, coronary artery disease, and cerebrovascular accidents compared to the general population. The specific mechanisms of anthracycline cardiotoxicity are complex and remain unclear. Hence, determining the factors that may increase susceptibility to cardiotoxicity is of great importance, as is monitoring patients during and after treatment. Additionally, treatment and prevention options, such as limiting cumulative dosage, liposomal anthracyclines, and dexrazoxane, continue to be explored. Here, we review the cardiovascular complications associated with the use of anthracyclines in treating malignancies in children and discuss methods for preventing, screening, and treating such complications in childhood cancer survivors.
39
Obrenovic-Kircanski, Biljana, Bojana Orbovic, Mile Vranes, Biljana Parapid, Natasa Kovacevic-Kostic, Milos Velinovic, and Stana Ristic. "Atrial fibrillation after coronary artery bypass surgery: Possibilities of prevention." Srpski arhiv za celokupno lekarstvo 140, no. 7-8 (2012): 521–27. http://dx.doi.org/10.2298/sarh1208521o.
Full textAbstract:
Atrial fibrillation occurs as a frequent complication after cardiac interventions. It can be found in 5% of all surgical patients, and it is far more common in cardiac (10% - 65% of patients) than in non-cardiac procedures. In a number of patients it remains asymptomatic, but may be accompanied by very severe symptoms of hypotension, heart failure, syncope, systemic or pulmonary embolism, perioperative myocardial infarction, cerebrovascular insult and increased operative mortality. Patients whose postoperative course is complicated by atrial fibrillation require longer hospitalization. Possible predisposing factors of this arrhythmia are numerous and are associated with surgery, extensive coronary heart disease and revascularization, and preoperative diseases. According to the recommendations of the European Society of Cardiology orally applied beta-blocker, amiodarone and sotalol can be used for prophylaxis of atrial fibrillation. Following the recommendations, treatment of postoperative atrial fibrillation should include beta-blockers, amiodarone, and in patients with heart failure and left ventricular dysfunction, digoxin. Due to the increased risk of stroke, an anticoagulant protection is necessary. Many studies have been conducted with results supporting the prophylactic use of amiodarone and beta-blockers, while the treatment with new agents such as magnesium, statins, omega-3 fatty acids and inhibitors of the renin-angiotensin-aldosterone system is still being investigated.
40
Arshinov, A. V., V. I. Emanuilov, and I. G. Maslova. "Cardiovascular complications in patients with rheumatic diseases." Clinical Medicine (Russian Journal) 96, no. 5 (October 12, 2018): 411–18. http://dx.doi.org/10.18821/0023-2149-2018-96-5-411-418.
Full textAbstract:
In the recent years, there are more and more reports stating an increased risk of atherosclerosis and cardiovascular complications in patients with rheumatic diseases. It should be noted that the development of atherosclerosis in this category of patients occurs much earlier than in the general population. Indeed, many rheumatic diseases are associated with an increased risk of developing of cardiovascular diseases and death from vascular accidents, including RA, systemic lupus erythematosus, ankylosing spondylitis, gout, psoriatic arthritis, vasculitis of the middle and large vessels. There are reports of an increased risk of cardiovascular disease in patients with systemic scleroderma. It is significant that rheumatic diseases and coronary heart disease combine common pathophysiological mechanisms - systemic and chronic inflammation. At the same time, traditional risk factors such as hypertension, old age, smoking, hypercholesterolemia, obesity and male sex can not fully explain the mechanism of accelerated development of atherosclerosis in patients with rheumatic diseases. The presence of specific risk factors, such as the duration of the course of treatment, glucocorticosteroids administration, the presence of an increased concentration of inflammatory mediators and autoimmune mechanisms create conditions for the acceleration of atherosclerosis in this group of patients. Coordination of efforts of rheumatologists and cardiologists in studying the mechanisms of accelerated development of atherosclerosis in patients with rheumatic diseases will allow to develop adequate methods for timely diagnosis and prevention of cardiovascular complications in patients with this widespread pathology.
41
Petrakova, E. S., N. M. Savina, and A. V. Molochkov. "Atrial Fibrillation After Coronary Artery Bypass Surgery: Risk Factors, Prevention and Treatment." Kardiologiia 60, no. 9 (September 15, 2020): 134–48. http://dx.doi.org/10.18087/cardio.2020.9.n1074.
Full textAbstract:
This review focuses on the issue of atrial fibrillation (AF) following coronary bypass surgery in patients with ischemic heart disease. Risk factors of this complication are discussed in detail. The authors addressed the effect of diabetes mellitus on development of postoperative AF. Data on current methods for prevention and treatment of AF are provided.
42
Pabivantsava, N. "JUSTIFICATION OF TECHNOLOGIES FOR ORGANIZING MEDICAL CARE FOR PATIENTS WITH HIGH CARDIOVASCULAR RISK ON THE EXAMPLE OF THE BREST REGION (PART 1)." Emergency Cardiology and Cardiovascular Risks 5, no. 1 (2021): 1234–38. http://dx.doi.org/10.51922/2616-633x.2021.5.2.1234.
Full textAbstract:
In order to substantiate organizational measures for early detection and tertiary prevention of cardiovascular diseases, the causal relationships of high morbidity, disability, and mortality due to cardiovascular diseases, coronary heart disease and its complications were studied in the population of the Brest region in the period from 2006 to 2010. Measures to improve the organization of preventive medical examination of patients from cardiovascular risk groups with prognostically unfavorable outcomes were suggested. Through the implementation of an organizational experiment in 2012-2017, it was possible to achieve a positive medical and social effect, expressed in increasing the availability of multi-level and high-tech care to patients in need, as well as in improving the medical and demographic indicators of the Brest region in general and in the diseases of the circulatory system in particular, which formed the basis of the second part of this article.
43
Capodanno, Davide, and Dominick J. Angiolillo. "Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus." Circulation 142, no. 22 (December 2020): 2172–88. http://dx.doi.org/10.1161/circulationaha.120.045465.
Full textAbstract:
Patients with diabetes mellitus (DM) are characterized by enhanced thrombotic risk attributed to multiple mechanisms including hyperreactive platelets, hypercoagulable status, and endothelial dysfunction. As such, they are more prone to atherosclerotic cardiovascular events than patients without DM, both before and after coronary artery disease (CAD) is established. In patients with DM without established CAD, primary prevention with aspirin is not routinely advocated because of its increased risk of major bleeding that largely offsets its ischemic benefit. In patients with DM with established CAD, secondary prevention with antiplatelet drugs is an asset of pharmacological strategies aimed at reducing the risk of atherosclerotic cardiovascular events and their adverse prognostic consequences. Such antithrombotic strategies include single antiplatelet therapy (eg, with aspirin or a P2Y 12 inhibitor), dual antiplatelet therapy (eg, aspirin combined with a P2Y 12 inhibitor), and dual-pathway inhibition (eg, aspirin combined with the vascular dose of the direct oral anticoagulant rivaroxaban) for patients with chronic ischemic heart disease, acute coronary syndromes, and those undergoing percutaneous coronary intervention. Because of their increased risk of thrombotic complications, patients with DM commonly achieve enhanced absolute benefit from more potent antithrombotic approaches compared with those without DM, which most often occurs at the expense of increased bleeding. Nevertheless, studies have shown that when excluding individuals at high risk for bleeding, the net clinical benefit favors the use of intensified long-term antithrombotic therapy in patients with DM and CAD. Several studies are ongoing to establish the role of novel antithrombotic strategies and drug formulations in maximizing the net benefit of antithrombotic therapy for patients with DM. The scope of this review article is to provide an overview of current and evolving antithrombotic strategies for primary and secondary prevention of atherosclerotic cardiovascular events in patients with CAD and DM.
44
Sachan, Neha, Dhiraj Kumar Srivastava, Pankaj Jain, Santosh Kumar Singh, Mahima, and Sushil Kumar Shukla. "Prevalence of complications of Type 2 Diabetes Mellitus and its association with different risk factors in Urban Etawah, Uttar Pradesh." Indian Journal of Community Health 33, no. 4 (December 31, 2021): 597–602. http://dx.doi.org/10.47203/ijch.2021.v33i04.010.
Full textAbstract:
Background- India is experiencing a rapid health transition, with large and rising burdens of chronic diseases, which were estimated to account for 53% of all deaths in 2005. Earlier estimates projected that the number of deaths attributable to chronic diseases would rise from 3·78 million in 1990 (40·4% of all deaths) to 7·63 million in 2020 (66·7% of all deaths). Aims and Objectives- To find out the prevalence of Complications of Type 2 Diabetes Mellitus and its association with different risk factors in Urban Etawah (U.P.) including tobacco, alcohol, fatty meals and physical activity. Material and Methods- The present study is a community-based study performed among 400 participants using cluster sampling technique in the field practice area of Urban health training centre, Department of Community Medicine, UPUMS, Saifai, Etawah. The participants were interviewed using a pre-tested questionnaire using Diabetes Complication Index. Results- Among the diabetics, the prevalence of coronary heart disease (CHD), peripheral vascular disease (PVD), cerebrovascular accidents (CVA), cataract, neuropathy and foot problems were 24%, 24%, 7%, 15.4%, 38%, 26% and 2% respectively. A statistically significant association was seen with fatty meals and complications. Conclusion - All the diabetic complications observed need to be addressed in prevention and control strategies in the study area. Heath screening camps will be organized for the people for awareness.
45
Ostanina, Yuliya O., Davyd A. Yakhontov, Yuliya D. Struts, and Anna A. Lyaskovskaya. "Clinical phenotypes of patients with ischemic heart disease and borderline coronary artery stenoses." Kazan medical journal 103, no. 6 (December 2, 2022): 928–36. http://dx.doi.org/10.17816/kmj100477.
Full textAbstract:
Background. Ischemic heart disease, despite ongoing therapeutic and preventive measures, remains the leading cause of disability and mortality in people of working age.
Aim. Study of cardiovascular risk factors and assessment of the clinical and angiographic picture in patients with stable coronary heart disease and borderline coronary artery stenoses of various clinical phenotypes.
Material and methods. 236 patients with functional class IIII stable angina pectoris aged 4959 years with borderline (4070%) coronary artery stenoses were examined. All patients underwent a general clinical examination, cardiac ultrasound and coronary angiography. The nonparametric MannWhitney U-test was used to compare indicators between groups. To compare binary and categorical indicators, Fisher's exact two-tailed test was used. Differences in the compared parameters were considered statistically significant at p 0.05.
Results. The predominance of the following clinical phenotypes, which determined the further distribution into groups, was revealed: coronary heart disease without myocardial infarction the first group; coronary heart disease with myocardial infarction more than 6 months old the second group; coronary heart disease with a metabolically unhealthy phenotype of obesity without diabetes mellitus the third group, coronary heart disease with diabetes mellitus the fourth group. In the third and fourth groups, there was no significant difference in the frequency of myocardial infarction in the past, and patients in the third group with a history of myocardial infarction suffered it at the earliest age (44.3 [41; 50] years, p 0.01). Despite the presence of arterial hypertension in 97.5% of groups of patients with different phenotypes, the fourth group showed the highest values of the left ventricular myocardium mass index (240.6 [146.3; 286.3], p 0.01). In the same group, multivessel coronary artery lesions were more frequently recorded during angiographic examination in 25 patients (47.2 [33.4; 52.3]%, p 0.01).
Conclusion. Despite the absence of obstructive coronary artery disease, patients with stable coronary heart disease and borderline coronary artery stenoses are at risk of cardiovascular complications due to the presence of arterial hypertension in the vast majority, a significant incidence of obesity, dyslipidemia, and carbohydrate metabolism disorders.
46
Veselovskaya, N. G., G. A. Chumakova, O. V. Gritsenko, and N. G. Mironova. "Predictors of development of cardiovascular events after stenting of coronary arteries at patients with obesity." CardioSomatics 5, no. 2 (June 15, 2014): 5–9. http://dx.doi.org/10.26442/cs45068.
Full textAbstract:
Aim. Study predictors of development of cardiovascular events after stenting of coronary arteries at patients with the coronary heart disease (CHD) with obesity.Material and methods. The study population included 186 (54,4±9,1 years) patients with coronary artery disease (CAD) and obesity undergoing percutaneous coronary intervention (PCI) with bare-metal stenting and at least 12 months of follow. The all patients research main and additional metabolic risk factors and epicardial fat thickness (EFT) with determination of echocardiography. Cardiovascular events were registered at 58 (31%) patients. The lipoprotein a - LP(а), leptin, blood glucose, interlaken-6, diastolic arterial pressure and index prevalence of coronary atherosclerosis on Gensini scale became predictors of cardiovascular events. The indicator of EFT showed interrelation with risk of a cardiovascular events. Conclusion. Determination of additional parameters of a lipid profile, carbohydrate metabolism, pro-inflammatory activity of plasma, neurohumoral activity of visceral fat and degree of epicardial adiposity is necessary for the purpose of formation of group of high risk of complications and carrying out prevention of risk factors before carrying out a coronary revascularization.
47
Vrána, Milan. "Prevention of cardiovascular complications with paroxetine in individuals with coronary heart disease and depressive/anxiety disorder. The PrevenPar project." Cor et Vasa 49, no. 4 (April 1, 2007): 147–51. http://dx.doi.org/10.33678/cor.2007.054.
Full text
48
Mu, Xiao-Min, Wei Wang, Yu-Ying Jiang, and Jia Feng. "Patterns of Comorbidity in Hepatocellular Carcinoma: A Network Perspective." International Journal of Environmental Research and Public Health 17, no. 9 (April 29, 2020): 3108. http://dx.doi.org/10.3390/ijerph17093108.
Full textAbstract:
Hepatocellular carcinoma (HCC) is a common and fatal cancer. People with HCC report higher odds of comorbidity compared with people without HCC. To explore the association between HCC and medical comorbidity, we used routinely collected clinical data and applied a network perspective. In the network perspective, we used correlation analysis and community detection tests that described direct relationships among comorbidities. We collected 14,891 patients with HCC living in Jilin Province, China, between 2016 and 2018. Cirrhosis was the most common comorbidity of HCC. Hypertension and renal cysts were more common in male patients, while chronic viral hepatitis C, hypersplenism, hypoproteinemia, anemia and coronary heart disease were more common in female patients. The proportion of chronic diseases in comorbidities increased with age. The main comorbidity patterns of HCC were: HCC, cirrhosis, chronic viral hepatitis B, portal hypertension, ascites and other common complications of cirrhosis; HCC, hypertension, diabetes mellitus, coronary heart disease and cerebral infarction; and HCC, hypoproteinemia, electrolyte disorders, gastrointestinal hemorrhage and hemorrhagic anemia. Our findings provide comprehensive information on comorbidity patterns of HCC, which may be used for the prevention and management of liver cancer.
49
Pokharel, Jeju Nath. "Perioperative ischaemia and management of patients with coronary stents: current practice." Journal of Society of Anesthesiologists of Nepal 1, no. 1 (October 3, 2015): 40–48. http://dx.doi.org/10.3126/jsan.v1i1.13588.
Full textAbstract:
Perioperative ischaemia is a common cause of cardiac morbidity and cardiac death during perioperative period in patient with coronary artery disease or with other risk factors. The incidence of perioperative ischaemia is about 20 to 70% in patient with coronary artery disease or coronary artery disease risk factors. Post operative cardiac events (the combined incidence of nonfatal myocardial infarction, unstable angina, heart failure and sudden cardiac death) vary between 5.5 to 53% and postoperative myocardial infarction varies between 1.4 to 43%. Prolonged ST- segment depression along with hypercoagulability caused by surgical stress, platelet activation, increased fibrinogen activity and decreased fibrinolytic activities may lead to coronary thrombosis, ischaemia, nonfatal infarction or sudden cardiac death. Patients with coronary stents especially before complete endothelialization of the stents are of high risk category for these complications. Anesthesiologist being a perioperative physician should understand safety issues of these patients to prevent from ischaemia, coronary thrombosis and subsequent infarction or sudden cardiac death. Risk identification, optimization, monitoring, diagnosis of the problem, prevention and management are very crucial during perioperative period to enhance the quality service and patient safety.Journal of Society of Anesthesiologists 2014 1(1): 40-48
50
Rublev, V. Y., E. A. Sergeev, and B. I. Geltser. "Hemodynamic indicators informativity in ischemic heart disease patients for forecasting results of coronary artery bypass grafting." Pacific Medical Journal, no. 1 (March 28, 2020): 16–22. http://dx.doi.org/10.34215/1609-1175-2020-1-16-22.
Full textAbstract:
The review presents an analysis of the scientific literature on the assessment of the predictive value of hemodynamic parameters for predicting the immediate and long-term results of coronary artery bypass grafting (CABG). Modern options for hemodynamic and volumetric monitoring are considered, including transesophageal echocardiography, prepulmonary, transpulmonary thermodilution, as well as other methods based on estimation of pulse wave transit time. The information content of individual hemodynamic parameters is discussed to optimize the early diagnosis, prevention and intensive care of cardiovascular events associated with CABG. The scientific literature on stratification of the risks of postoperative complications and mortality based on the analysis of the predictive value of hemodynamic parameters is generalized. Variants of the integrated application of hemodynamic monitoring methods and artificial intelligence technologies for the development of automated systems for predicting the near and long-term results of CABG are analyzed.